JP2023099094A5 - - Google Patents

Download PDF

Info

Publication number
JP2023099094A5
JP2023099094A5 JP2023073187A JP2023073187A JP2023099094A5 JP 2023099094 A5 JP2023099094 A5 JP 2023099094A5 JP 2023073187 A JP2023073187 A JP 2023073187A JP 2023073187 A JP2023073187 A JP 2023073187A JP 2023099094 A5 JP2023099094 A5 JP 2023099094A5
Authority
JP
Japan
Prior art keywords
initiation
treatment
monthly
disease
administrations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023073187A
Other languages
English (en)
Japanese (ja)
Other versions
JP7646727B2 (ja
JP2023099094A (ja
Filing date
Publication date
Priority claimed from JP2022000341A external-priority patent/JP7273204B2/ja
Application filed filed Critical
Publication of JP2023099094A publication Critical patent/JP2023099094A/ja
Publication of JP2023099094A5 publication Critical patent/JP2023099094A5/ja
Priority to JP2025034492A priority Critical patent/JP7852107B2/ja
Priority to JP2025034493A priority patent/JP7852108B2/ja
Application granted granted Critical
Publication of JP7646727B2 publication Critical patent/JP7646727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023073187A 2018-02-06 2023-04-27 眼科疾患の処置 Active JP7646727B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025034492A JP7852107B2 (ja) 2018-02-06 2025-03-05 眼科疾患の処置
JP2025034493A JP7852108B2 (ja) 2018-02-06 2025-03-05 眼科疾患の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US62/627,103 2018-02-06
US201862729333P 2018-09-10 2018-09-10
US62/729,333 2018-09-10
JP2022000341A JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022000341A Division JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025034492A Division JP7852107B2 (ja) 2018-02-06 2025-03-05 眼科疾患の処置
JP2025034493A Division JP7852108B2 (ja) 2018-02-06 2025-03-05 眼科疾患の処置

Publications (3)

Publication Number Publication Date
JP2023099094A JP2023099094A (ja) 2023-07-11
JP2023099094A5 true JP2023099094A5 (https=) 2024-12-20
JP7646727B2 JP7646727B2 (ja) 2025-03-17

Family

ID=65352014

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2020536578A Active JP7005772B2 (ja) 2018-02-06 2019-02-05 眼科疾患の処置
JP2022000341A Active JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置
JP2023073187A Active JP7646727B2 (ja) 2018-02-06 2023-04-27 眼科疾患の処置
JP2025034492A Active JP7852107B2 (ja) 2018-02-06 2025-03-05 眼科疾患の処置
JP2025034493A Active JP7852108B2 (ja) 2018-02-06 2025-03-05 眼科疾患の処置

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020536578A Active JP7005772B2 (ja) 2018-02-06 2019-02-05 眼科疾患の処置
JP2022000341A Active JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025034492A Active JP7852107B2 (ja) 2018-02-06 2025-03-05 眼科疾患の処置
JP2025034493A Active JP7852108B2 (ja) 2018-02-06 2025-03-05 眼科疾患の処置

Country Status (12)

Country Link
US (2) US20210139576A1 (https=)
EP (1) EP3749359A1 (https=)
JP (5) JP7005772B2 (https=)
KR (3) KR20250166355A (https=)
CN (4) CN111699004A (https=)
AU (3) AU2019219004B2 (https=)
CA (1) CA3088355A1 (https=)
IL (1) IL276383B2 (https=)
MX (1) MX2020007527A (https=)
SG (1) SG11202006712XA (https=)
TW (3) TWI831764B (https=)
WO (1) WO2019154776A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
TWI785360B (zh) * 2019-08-06 2022-12-01 美商建南德克公司 眼科疾病之個人化治療
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
EP4208201A1 (en) * 2020-09-04 2023-07-12 F. Hoffmann-La Roche AG Antibody that binds to vegf-a and ang2 and methods of use
WO2022057888A1 (zh) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
JP2024512701A (ja) * 2021-03-30 2024-03-19 アブプロ コーポレーション 抗ang2×vegf多重特異性抗体を用いて脈絡膜新生血管形成を治療するための方法
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CN118139628A (zh) * 2021-08-23 2024-06-04 阿维麦克思生物制药公司 用于转基因表达的组合物和方法
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-vegf 항체
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス 二重特異性抗体の生産
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
SG11201408538PA (en) * 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CA2879597C (en) * 2012-08-21 2021-01-12 Opko Pharmaceuticals, Llc Ophthalmic liposome formulations for treating posterior segment disease
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN114306575A (zh) * 2014-12-11 2022-04-12 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
EP3454903A4 (en) 2016-05-13 2020-08-19 Askgene Pharma, Inc. NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF
EP4549463A3 (en) * 2016-06-17 2025-07-30 F. Hoffmann-La Roche AG Purification of multispecific antibodies

Similar Documents

Publication Publication Date Title
JP2023099094A5 (https=)
JP2025084976A5 (https=)
JP2025084977A5 (https=)
KR102412023B1 (ko) 레날리도마이드 또는 포말리도마이드 및 cd38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도
IL276383B2 (en) Treatment of ophthalmologic diseases
CN109715189B (zh) 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
US20100047204A1 (en) Use of organic compounds
CN111787981B (zh) 增加肌肉量和减少脂肪量的方法
CN109071656A (zh) 检查点调节物拮抗剂
CA3118777A1 (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
CN106794244A (zh) 用于降低心血管风险的方法
JP2024519629A5 (https=)
JP2025530139A (ja) 抗FcRN抗体を用いた慢性炎症性脱髄性多発神経障害の治療方法
JP2017535285A5 (https=)
JP2019521156A5 (https=)
JP2022553640A5 (https=)
US20130004486A1 (en) Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
JP7722991B2 (ja) 抗fcrn抗体を用いた温熱自己免疫性溶血性貧血の治療方法
CN116710137A (zh) 用于在治疗眼部疾病的方法中使用的vegf拮抗剂
JP2021523881A5 (https=)
JP2009538916A5 (https=)
TW202237181A (zh) 治療眼部疾病之方法
JP2025528527A (ja) 抗FcRN抗体を用いたグレーブス病の治療方法
WO2018096467A1 (en) Methods of treating acne using interleukin-17 (il-17) antagonists
HK40121539A (zh) 使用抗fcrn抗体治疗慢性炎性脱髓鞘性多发性神经病的方法